Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 24;12(2):e0172324.
doi: 10.1371/journal.pone.0172324. eCollection 2017.

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients

Yunbao Pan  1 , Yufen Yuan  2 , Guoshi Liu  3 , Yongchang Wei  4
Affiliations

P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients

Yunbao Pan et al. PLoS One. .

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer lack of effective target therapy. This study was to investigate the prognostic role of p53 and Ki-67 in 156 cases of TNBC patients. Logistic regression analysis was used to examine the association between clinical parameters and recurrence. Univariate and multivariate analyses were used to examine the association between clinical characteristics and disease-free survival (DFS) or overall survival (OS). Survival analyses using the Kaplan-Meier method were performed to examine the association between p53/Ki-67 and DFS and OS. Our data showed that p53 was positive in 71.3% and the Ki-67 high index was in 82.8% of TNBC. Elevated p53 and Ki-67 were associated with histological grade. The tumor size, lymph node involvement, and p53 expression are associated with risk of recurrence. Tumor size, lymph node involvement, family history, Ki-67 and p53 are independent variables associated with either DFS or OS. TNBC patients with positive p53 or Ki-67 high index or family history of cancer have a significant association with worse prognosis. This study suggests that p53, Ki-67 and family history are useful prognostic markers in TNBC.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. HE staining of TNBC tissue.
(A) Lobular cancer. (B) Ductal cancer. (C)Medullary cancer.
Fig 2
Fig 2. Immunohistochemical analysis of p53 and Ki-67 in TNBC.
(A) Negative and positive p53 staining. (B) Negative and positive Ki-67 staining.
Fig 3
Fig 3. P53 and Ki-67 associates with tumor grade in TNBC.
Box plots indicating the distribution of the p53 (A) and Ki-67 (B) and tumor grade, P values were from one-way ANOVA and LSD tests. (C) P53 and Ki-67 was associated with tumor grade in TNBC. (D) P53 was associated with Ki-67 in TNBC. The R and P values were from Pearson Correlation.
Fig 4
Fig 4. P53, Ki-67 and family history predict survival in TNBC.
Estimated disease-free survival (DFS) (A) and overall survival (OS) (B) curves for p53, Ki-67 and family history.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87–108. - PubMed
    1. Adamo V, Ricciardi GR, De Placido S, Colucci G, Conte P, Giuffrida D, et al. Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. European journal of cancer. 2012;48(5):642–7. 10.1016/j.ejca.2011.06.028 - DOI - PubMed
    1. Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2016. - PMC - PubMed
    1. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast cancer research and treatment. 2012;132(2):523–35. PubMed Central PMCID: PMC3303043. 10.1007/s10549-011-1619-7 - DOI - PMC - PubMed
    1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature reviews Clinical oncology. 2016;13(11):674–90. 10.1038/nrclinonc.2016.66 - DOI - PMC - PubMed